Sarker Malabika, Ruiz-Ruiz Carmen, Robledo Gema, López-Rivas Abelardo
Instituto de Parasitología y Biomedicina CSIC, calle Ventanilla 11, 18001 Granada, Spain.
Oncogene. 2002 Jun 20;21(27):4323-7. doi: 10.1038/sj.onc.1205523.
We studied the role of the mitogen-activated protein kinase (MAPK) pathway in the regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in breast tumor MCF-7 cells. We found that addition of a protein kinase C (PKC) activator to MCF-7 cultures prevented TRAIL-induced apoptosis, by inhibiting a step downstream of both caspase-8 activation and BID cleavage. TRAIL-induced translocation of Bax from cytosol to mitochondria, release of cytochrome c from mitochondria and activation of caspase-9 were all inhibited by PKC activation. PKC-mediated prevention of mitochondrial apoptotic events and apoptosis was found to be dependent on the MAPK pathway. Since TRAIL is a ligand of potential use in antineoplastic clinical trials, our findings may provide relevant information in cancer therapy.
我们研究了丝裂原活化蛋白激酶(MAPK)通路在调节肿瘤坏死因子相关凋亡诱导配体(TRAIL)介导的乳腺癌MCF-7细胞凋亡中的作用。我们发现,向MCF-7培养物中添加蛋白激酶C(PKC)激活剂可通过抑制半胱天冬酶-8激活和BID裂解下游的一个步骤来阻止TRAIL诱导的凋亡。TRAIL诱导的Bax从细胞质转位至线粒体、细胞色素c从线粒体释放以及半胱天冬酶-9的激活均受到PKC激活的抑制。发现PKC介导的对线粒体凋亡事件和凋亡的预防依赖于MAPK通路。由于TRAIL是一种可能用于抗肿瘤临床试验的配体,我们的发现可能为癌症治疗提供相关信息。